January–June 2026 compared with January–June 2025 Net sales declined 6% to SEK 9,893m (10,541). The lower net sales were mainly driven by lower selling prices and negative exchange rate effects, which were offset by higher delivery volumes. EBITDA amounted to SEK 2,410m (3,684). The decrease was primarily attributable to lower selling prices, negative exchange rate effects and higher raw material costs.
EU approves SCA's acquisition of Georgia-Pacific's European tissue business
- Regulatory press release
The European Commission has today, 5 July 2012, approved SCA's acquisition of Georgia-Pacific's European tissue business. The purchase price amounts to EUR 1.32 bn on a debt free basis. The operations have approximately 4,700 employees.
The acquisition confirms SCA’s position as a European leader in the industry with an enhanced, integrated European tissue business and well-known brands.
Georgia-Pacific’s European tissue business, which comprises of15 plants located in seven countries and the well-known Lotus brand, will be transferred to SCA´s ownership in connection with the closing of the deal which is expected 20 July.
EU´s clearance requires divestment of Georgia-Pacific´s consumer tissue business in the UK including production capacity, Georgia-Pacific´s Benelux consumer tissue branded business under the Lotus brand and some of Georgia-Pacific´s and SCA`s retailer branded business in Scandinavia including production capacity.
See also previous press releases dated 10 November 2011 and 8 February 2012.
For additional information, please contact:
Pär Altan, Vice President Media Relations, +46 8 788 5237
Johan Karlsson, Vice President Investor Relations, +46 8 788 5130
NB: This information is such that SCA must disclose in accordance with the Securities Markets Act.
The information was submitted for publication on 5 July 2012 at 13.00 CET.